AMZN
Amazon.com, Inc.
AMZN has the edge over CCS overall, supported by stronger valuation and stronger modeled upside.
CCS
Century Communities, Inc.
CCS trails on the overall score without a compensating advantage in the available component scores.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
CCS Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Under pressure | |
| Stable |
CCS's profitability and balance sheet are currently stable, but its revenue and cash flow are under pressure.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN has the edge over CCS in the historical PE scenario, which offers more potential upside but is not a forecast.
CCS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 4.2x | $15.75 | -70% |
| Fair | 8x | $29.98 | -42% |
| Expensive | 11x | $39.91 | -23% |
| Current | 14x | $51.92 | — |
| Forward | 27x | $51.92 | — |
Historical ranges are pointers, not guarantees.
CCS's PE is in its expensive range at 14x. Analysts expect earnings to fall, which would put today's price at 27x next year's earnings.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
AMZN has the edge over CCS on the outlook, with more favorable earnings and revenue expectations.
CCS Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong decline | |
| Stable | |
| Weakening | |
| Limited | |
| High |
Analysts expect CCS's earnings and profitability to decline, with its revenue holding steady.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN has the edge over CCS on earnings, with more consistent year-over-year improvement.
CCS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.89 | -50% |
| Q3 2026 | $3.75 | -45% |
| Q2 2026 | $4.56 | -44% |
| Q1 2026 | $4.44 | -54% |
| Q4 2025 | $4.86 | -53% |
| Q3 2025 | $6.85 | -32% |
| Q2 2025 | $8.19 | -18% |
| Q1 2025 | $9.66 | +7.2% |
| Q4 2024 | $10.40 | +29% |
CCS's earnings per share have fallen from their peak: $3.75 over the past year, against $18.20 in late 2022.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
AMZN has the edge over CCS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN has the edge over CCS on profitability, with a higher operating margin.
CCS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $864.5M | -12% |
| Q2 2026 | $927.2M | -7.3% |
| Q1 2026 | $789.7M | -13% |
| Q4 2025 | $1.2B | -3.1% |
| Q3 2025 | $980.3M | -14% |
| Q2 2025 | $1B | -3.7% |
| Q1 2025 | $903.2M | -4.8% |
| Q4 2024 | $1.3B | +5.6% |
CCS's revenue has slid since its 2024 peak: $864M last quarter, down 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.8% | -3 points |
| Q2 2026 | 5.3% | +0.6 points |
| Q1 2026 | 4.2% | -1.6 points |
| Q4 2025 | 3.8% | -6.8 points |
| Q3 2025 | 4.9% | -4.8 points |
| Q2 2025 | 4.7% | -5.9 points |
| Q1 2025 | 5.8% | -3.1 points |
| Q4 2024 | 11% | +0.2 points |
CCS's operating margin was 1.8% last quarter, down 3 points from the same quarter a year ago, near the bottom of its range since 2019.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
AMZN's free cash flow was −$46.9B over the past year, against $10.6B the year before.
CCS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$142.4M | -$121.6M |
| Q2 2026 | -$89.6M | -$72.1M |
| Q1 2026 | -$57.1M | -$17.1M |
| Q4 2025 | $202.6M | -30% |
| Q3 2025 | -$20.8M | +$81.1M |
| Q2 2025 | -$17.6M | +$100.1M |
| Q1 2025 | -$40M | -355% |
| Q4 2024 | $290.6M | +$310.6M |
CCS has the edge over AMZN on cash flow, with more consistent year-over-year improvement.
AMZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +26M shares |
| 1 year | +0.8% | +84M shares |
| 3 years | +3.5% | +371M shares |
| 5 years | +6.1% | +629M shares |
| Available history | +8.2% | +829M shares |
AMZN has 10.9B diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $3.3B |
CCS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -177K shares |
| 1 year | -5.1% | -1.5M shares |
| 3 years | -12% | -3.8M shares |
| 5 years | -17% | -6M shares |
| Available history | -8.7% | -2.7M shares |
CCS has the edge over AMZN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $11.6M |
| Q2 2026 | $19.6M |
| Q1 2026 | $40M |
| Q4 2025 | $20M |
| Q3 2025 | $20M |
| Q2 2025 | $48M |
| Q1 2025 | $55.6M |
| Q4 2024 | $30.7M |
CCS spent $91M buying back its own shares over the past year, down 41% from the year before.
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN has the edge over CCS on leverage, with a lower net debt burden relative to earnings.
CCS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.2x | Moderate |
| Q2 2026 | 1.2x | Healthy |
| Q1 2026 | 0.6x | Very low |
| Q4 2025 | -0.3x | Net Cash |
| Q3 2025 | 0.7x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.3x | Very low |
| Q4 2024 | -0.0x | Net Cash |
CCS's net debt is about 2.2 years of its operating earnings (EBITDA), up from less than a year a year ago.
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
CCS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.0 | Neutral |
| Stochastic | 12.1 | Oversold |
CCS's weekly RSI is 39 (neutral) and its Stochastic is 12 (oversold).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN is trading at 22x earnings, a 20% premium to the Consumer Cyclical sector's median of 18x, though its recent earnings include one-off gains.
CCS PE vs Consumer Cyclical Sector
| Metric | CCS | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 18x | 23% below |
| PE % | 95 | 47 | 48 pts above |
CCS has the edge over AMZN on valuation relative to its sector.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN has the edge over CCS on trend strength, trading above more of its moving averages.
CCS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $56.3 | 7.8% below |
| 20 week MA | $62.7 | 17% below |
| 50 week MA | $61.8 | 16% below |
| 100 week MA | $62.7 | 17% below |
| 200 week MA | $70.9 | 27% below |
CCS is in a downtrend: it's below all five of its weekly moving averages, and 27% below its 200-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has the edge over CCS on returns for 2026, with the stronger performance.
CCS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $27.3 | $47.5 | +74% |
| 2021 | $47.5 | $79.5 | +67% |
| 2022 | $79.5 | $51.4 | -35% |
| 2023 | $51.4 | $91.1 | +77% |
| 2024 | $91.1 | $73.6 | -19% |
| 2025 | $73.6 | $59.0 | -20% |
| 2026 YTD | $59.0 | $51.9 | -12% |
CCS has finished lower in three of the last six years. It's down 12% so far in 2026.